We are live on ! Find out more
CLDI icon

Calidi Biotherapeutics
CLDI

34 hedge funds and large institutions have $656K invested in Calidi Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.06% less ownership

Funds ownership: 0.11% → 0.05% (-0.06%)

3% less funds holding

Funds holding: 35 → 34 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

79% less capital invested

Capital invested by funds: $3.09M → $656K (-$2.44M)

Holders
34
Holders Change
-1
Holders Change %
-2.86%
% of All Funds
0.45%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
5
Increased
4
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$28.8K
2
UBS Group
UBS Group
Switzerland
+$18.2K
3
HF
HRT Financial
New York
+$17.6K
4
Raymond James Financial
Raymond James Financial
Florida
+$12.6K
5
Goldman Sachs
Goldman Sachs
New York
+$5.36K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.02M
2
RCI
RS Crum Inc
California
-$31.3K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$27.2K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$18.5K
5
VF
Virtu Financial
New York
-$18K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$182K -$1.02M -13,177 -76%
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$97.2K -$27.2K -350 -14%
Vanguard Group
3
Vanguard Group
Pennsylvania
$81.3K – – –
BAM
4
Belpointe Asset Management
Nevada
$57.5K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$53.5K -$7.85K -101 -8%
HighTower Advisors
6
HighTower Advisors
Illinois
$27.5K – – –
CI
7
CPR Investments
Michigan
$23.2K – – –
RWI
8
Red Wave Investments
Pennsylvania
$18.6K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$16.4K +$28.8K +371 New
State Street
10
State Street
Massachusetts
$14.1K – – –
Northern Trust
11
Northern Trust
Illinois
$11.2K – – –
DWM
12
Drive Wealth Management
Utah
$10.3K -$4.04K -52 -18%
UBS Group
13
UBS Group
Switzerland
$10.3K +$18.2K +234 New
HF
14
HRT Financial
New York
$10K +$17.6K +227 New
Raymond James Financial
15
Raymond James Financial
Florida
$7.15K +$12.6K +162 New
Osaic Holdings
16
Osaic Holdings
Arizona
$6.15K +$3.03K +39 +39%
DIM
17
Delta Investment Management
California
$4.83K – – –
Goldman Sachs
18
Goldman Sachs
New York
$3.04K +$5.36K +69 New
Commonwealth Equity Services
19
Commonwealth Equity Services
Massachusetts
$3K – – –
HCM
20
Highbridge Capital Management
New York
$2.88K – – –
FC
21
Finepoint Capital
Massachusetts
$2.88K – – –
AWE
22
Avidian Wealth Enterprises
Texas
$2.3K – – –
TRCT
23
Tower Research Capital (TRC)
New York
$2.06K +$1.55K +20 +74%
VF
24
Virtu Financial
New York
$2K -$18K -232 -81%
GIM
25
Grassi Investment Management
California
$2K – – –
1
2

CLDI Hedge Fund Activity: Q2 2025 in Review

34 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q2 2025, worth a combined $656K — down 79% from $3.09M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CLDI and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $28.8K. The largest seller was Armistice Capital, cutting an estimated $1.02M.

  • 34 institutional investors held Calidi Biotherapeutics (CLDI) as of Q2 2025, down from 35 in Q1 2025.
  • Funds reported $656K of Calidi Biotherapeutics stock for Q2 2025, down 79% quarter-over-quarter.
  • 5 funds opened new Calidi Biotherapeutics positions in Q2 2025 and 6 closed out, a net change of -1 holder.
  • The largest Calidi Biotherapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $28.8K added.
  • The largest Calidi Biotherapeutics seller in Q2 2025 was Armistice Capital, an estimated $1.02M sold.

Based on aggregated 13F filings for Q2 2025.